7RJ2
| |
7RHN
| |
7RHM
| |
7RAO
| |
7T13
| |
7T12
| |
7M9F
| |
7MN0
| |
7MKC
| |
7NQQ
| |
7NQW
| Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2 | 分子名称: | 6-[5-chloranyl-2-(oxan-4-ylamino)pyrimidin-4-yl]-2-[2-oxidanylidene-2-(1,3,4,5-tetrahydro-2-benzazepin-2-yl)ethyl]-3~{H}-isoindol-1-one, DIMETHYL SULFOXIDE, Mitogen-activated protein kinase 1, ... | 著者 | O'Reilly, M. | 登録日 | 2021-03-02 | 公開日 | 2021-10-06 | 実験手法 | X-RAY DIFFRACTION (1.775 Å) | 主引用文献 | Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2. J.Med.Chem., 64, 2021
|
|
7N9V
| |
7N9U
| CA-targeting nanobody is a tool for studying HIV-1 capsid lattice interactions | 分子名称: | Capsid protein, Nanobody | 著者 | Gerber, E.E, Digianantonio, K.M, Tripler, T.N, Smaga, S.S, Summers, B.J, Xiong, Y. | 登録日 | 2021-06-18 | 公開日 | 2022-06-22 | 最終更新日 | 2023-10-18 | 実験手法 | X-RAY DIFFRACTION (3.19 Å) | 主引用文献 | CA-targeting nanobody is a tool for studying HIV-1 capsid lattice interactions To Be Published
|
|
7NR3
| Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2 | 分子名称: | 6-[5-chloranyl-2-(oxan-4-ylamino)pyrimidin-4-yl]-2-[2-oxidanylidene-2-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)ethyl]-3~{H}-isoindol-1-one, Mitogen-activated protein kinase 1, SULFATE ION | 著者 | O'Reilly, M. | 登録日 | 2021-03-02 | 公開日 | 2021-10-06 | 実験手法 | X-RAY DIFFRACTION (1.897 Å) | 主引用文献 | Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2. J.Med.Chem., 64, 2021
|
|
7NR9
| |
7NR8
| Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2 | 分子名称: | (2~{R})-2-[5-[5-chloranyl-2-(oxan-4-ylamino)pyrimidin-4-yl]-3-oxidanylidene-1~{H}-isoindol-2-yl]-~{N}-[(1~{S})-1-[6-(4-methylpiperazin-1-yl)pyridin-2-yl]-2-oxidanyl-ethyl]propanamide, 1,2-ETHANEDIOL, DIMETHYL SULFOXIDE, ... | 著者 | O'Reilly, M, Cleasby, A. | 登録日 | 2021-03-03 | 公開日 | 2021-10-06 | 実験手法 | X-RAY DIFFRACTION (1.627 Å) | 主引用文献 | Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2. J.Med.Chem., 64, 2021
|
|
7NR5
| Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2 | 分子名称: | (2~{R})-2-[5-[5-chloranyl-2-[(2-methyl-1,2,3-triazol-4-yl)amino]pyrimidin-4-yl]-3-oxidanylidene-1~{H}-isoindol-2-yl]-~{N}-[(1~{S})-1-(3-fluoranyl-5-methoxy-phenyl)-2-oxidanyl-ethyl]propanamide, Mitogen-activated protein kinase 1, SULFATE ION | 著者 | O'Reilly, M, Cleasby, A. | 登録日 | 2021-03-03 | 公開日 | 2021-10-06 | 実験手法 | X-RAY DIFFRACTION (1.766 Å) | 主引用文献 | Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2. J.Med.Chem., 64, 2021
|
|
7MFE
| Autoinhibited BRAF:(14-3-3)2 complex with the BRAF RBD resolved | 分子名称: | 14-3-3 protein zeta/delta, Serine/threonine-protein kinase B-raf, ZINC ION | 著者 | Martinez Fiesco, J.A, Ping, Z, Durrant, D.E, Morrison, D.K. | 登録日 | 2021-04-09 | 公開日 | 2022-01-26 | 最終更新日 | 2022-02-09 | 実験手法 | ELECTRON MICROSCOPY (4.07 Å) | 主引用文献 | Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding. Nat Commun, 13, 2022
|
|
7MFF
| Dimeric (BRAF)2:(14-3-3)2 complex bound to SB590885 Inhibitor | 分子名称: | (1Z)-5-(2-{4-[2-(DIMETHYLAMINO)ETHOXY]PHENYL}-5-PYRIDIN-4-YL-1H-IMIDAZOL-4-YL)INDAN-1-ONE OXIME, 14-3-3 protein zeta/delta, Serine/threonine-protein kinase B-raf | 著者 | Martinez Fiesco, J.A, Ping, Z, Durrant, D.E, Morrison, D.K. | 登録日 | 2021-04-09 | 公開日 | 2022-01-26 | 最終更新日 | 2022-02-09 | 実験手法 | ELECTRON MICROSCOPY (3.89 Å) | 主引用文献 | Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding. Nat Commun, 13, 2022
|
|
8CL1
| |
8CKZ
| |
8CKX
| |
8CKY
| |
8CKV
| |
8CL3
| |